Velsipity® 2 mg film-coated tablets
*Company:
Pfizer Healthcare Ireland Unlimited CompanyStatus:
UpdatedLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
This medicinal product is subject to additional monitoring.
*Additional information is available within the SPC or upon request to the company
Updated on 27 August 2025
File name
Adv SPC VL 5_0 IE - clean.pdf
Reasons for updating
- Change to section 6.5 - Nature and contents of container
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The SPC has been updated as follows: Section 6.5 Change in blister packaging Aluminium blister strip laminated to an oriented polyamine (oPA) film and integrated desiccant layer (HDPE/LDPE), with a aluminium/LDPE backing.
Updated on 26 August 2025
File name
Adv SPC VL 5_0 IE - clean.pdf
Reasons for updating
- Change to section 6.5 - Nature and contents of container
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The SPC has been updated as follows: Section 6.5 Change in blister packaging ‘Aluminium blister strip laminated to an oriented polyamine (oPA) film and integrated desiccant layer (HDPE/LDPE), with an paper/aluminium/LDPE backing.’
Updated on 18 June 2025
File name
clean Adv SPC VL 3_0 IE .pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The SPC has been updated as follows:
Section 4.4 updated with revised wording for the caution when co‑administering etrasimod and anti‑neoplastic, immune‑modulating, or immunosuppressive (including corticosteroid) therapies.
Section 10 updated with date of revised text and reference.
Updated on 18 June 2025
File name
clean Adv PIL VL 3_0 IE .pdf
Reasons for updating
- Change to section 3 - overdose, missed or forgotten doses
- Change to section 4 - how to report a side effect
- Change to section 6 - marketing authorisation holder
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
The PIL has been updated as follows:
Section 3, revised text for if you forget to take a dose
Section 4, minor update from “If you get any side effects, talk to your doctor, pharmacist or nurse.” to “If you get any side effects, talk to your doctor or pharmacist.” Deletion of details for United Kingdom (Northern Ireland)
Section 6, Update from Pfizer Healthcare Ireland to Pfizer Healthcare Unlimited Company and Deletion of details for United Kingdom (Northern Ireland). Also, update to revision date and reference
Updated on 07 January 2025
File name
Adv SPC VL 2_5 IE.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Launch Date: 3rd Jan 2025
Updated on 07 January 2025
File name
Adv PIL VL 2_2 IE NI.pdf
Reasons for updating
- New PIL for new product
Pfizer Healthcare Ireland Unlimited Company
Address:
The Watermarque Building, Ringsend Road, Dublin 4, D04 K7N3, IrelandTelephone:
+353 1 467 6500Fax:
+353 1 467 6501Website:
https://www.pfizermedicalinformation.ie/Medical Information Direct Line:
1 800 633 363